Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H19NO5 |
Molecular Weight | 233.2616 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CO)[C@@H](O)C(=O)NCCCC(O)=O
InChI
InChIKey=SBBDHANTMHIRGW-QMMMGPOBSA-N
InChI=1S/C10H19NO5/c1-10(2,6-12)8(15)9(16)11-5-3-4-7(13)14/h8,12,15H,3-6H2,1-2H3,(H,11,16)(H,13,14)/t8-/m0/s1
Molecular Formula | C10H19NO5 |
Molecular Weight | 233.2616 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Hopantenic acid (homopantothenic acid) is a central nervous system depressant. Formulated as the calcium salt, it is used as a pharmaceutical drug in the Russian Federation under the brand name Pantogam. In Russia it is widely used to treat a variety of neurological, psychological and psychiatric conditions. The drug has been on the pharmaceutical market since 1979 and has been proven to be safe even for children from 3 years old upwards. Hopantenic acid is a natural forming substance, has some of the lowest side effects and considered to be very safe. Use Pantogam to treat a wide variety of cognitive and nervous system disorders with combined sedative and mild stimulant effect. Hopantenic acid is not approved for use in Europe or the United States. GABA receptor agonist.
Originator
Sources: http://www.biochemj.org/content/36/3-4/357
Curator's Comment: Hopantenic acid that was firstly synthesized in Japan in the beginning of 1950s
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111463 |
|||
Target ID: CHEMBL2111474 |
100.0 µM [IC50] | ||
Target ID: CHEMBL1907607 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PANTOGAM Approved UseUSES
Improves Mental and Physical Ability
Become More Calm
Erradicate Mood Swings
Treat Epilepsy in Both Adults and Children
Reduce Hyperactivity in Children
Treat Attention Deficit Disorders
Treat Nerve Ticks |
|||
Primary | PANTOGAM Approved UseIndications
• congitive affections due to organic impairments of the brain (including consequences of neuro-infections and craniocerebral traumas) and neurotic disturbances;
• schizophrenia with a cerebral organic insufficiency ;
• • cerebrovascular insufficiency due to aterosclerotic changes of the brain;
• extrapyramid hyper-kinesises (myoclonus epilepsy, Huntingtone's chorea, hepato-lenticular degeneration, Parkinson's disease etc.), for treatment of the extrapyramid syndrome due to a neuroleptics use;
• epilepsy with deceleration of psychic processes and a decrease of a cognitive productivity (in combination with anti-convulsive drugs);
• psycho-emotional overloads, a decrease of the mental and physical workability, for an improvement of an attention concentration and memorization;
• neurogenous disturbances of urination (pollakiuria, imperative feelings of urination, imperative urinary incontinence, enuresis);
• children with a perinatal encephalopathy; mental retardation of a different severity (including that with behavioral disturbances); psychology state affections in children, like a common psychic development retardation, specific speech disturbances, motoric functions and combined states; hyperkinetic disturbances, including a hyperactivity syndrome with an attention deficiency; neurosis-like states (stammering (preferably a clonic form), tics). |
|||
Primary | PANTOGAM Approved UseIndications
• congitive affections due to organic impairments of the brain (including consequences of neuro-infections and craniocerebral traumas) and neurotic disturbances;
• schizophrenia with a cerebral organic insufficiency ;
• • cerebrovascular insufficiency due to aterosclerotic changes of the brain;
• extrapyramid hyper-kinesises (myoclonus epilepsy, Huntingtone's chorea, hepato-lenticular degeneration, Parkinson's disease etc.), for treatment of the extrapyramid syndrome due to a neuroleptics use;
• epilepsy with deceleration of psychic processes and a decrease of a cognitive productivity (in combination with anti-convulsive drugs);
• psycho-emotional overloads, a decrease of the mental and physical workability, for an improvement of an attention concentration and memorization;
• neurogenous disturbances of urination (pollakiuria, imperative feelings of urination, imperative urinary incontinence, enuresis);
• children with a perinatal encephalopathy; mental retardation of a different severity (including that with behavioral disturbances); psychology state affections in children, like a common psychic development retardation, specific speech disturbances, motoric functions and combined states; hyperkinetic disturbances, including a hyperactivity syndrome with an attention deficiency; neurosis-like states (stammering (preferably a clonic form), tics). |
|||
Primary | PANTOGAM Approved UseIndications
• congitive affections due to organic impairments of the brain (including consequences of neuro-infections and craniocerebral traumas) and neurotic disturbances;
• schizophrenia with a cerebral organic insufficiency ;
• • cerebrovascular insufficiency due to aterosclerotic changes of the brain;
• extrapyramid hyper-kinesises (myoclonus epilepsy, Huntingtone's chorea, hepato-lenticular degeneration, Parkinson's disease etc.), for treatment of the extrapyramid syndrome due to a neuroleptics use;
• epilepsy with deceleration of psychic processes and a decrease of a cognitive productivity (in combination with anti-convulsive drugs);
• psycho-emotional overloads, a decrease of the mental and physical workability, for an improvement of an attention concentration and memorization;
• neurogenous disturbances of urination (pollakiuria, imperative feelings of urination, imperative urinary incontinence, enuresis);
• children with a perinatal encephalopathy; mental retardation of a different severity (including that with behavioral disturbances); psychology state affections in children, like a common psychic development retardation, specific speech disturbances, motoric functions and combined states; hyperkinetic disturbances, including a hyperactivity syndrome with an attention deficiency; neurosis-like states (stammering (preferably a clonic form), tics). |
Sample Use Guides
In Vivo Use Guide
Sources: http://rupharma.com/pantogam/
To be taken orally 15-30 minutes after breakfast and lunch.
Can be taken by children from 3 years old upwards.
For adults:
Single dose 250-1000 mg, daily dose 1500-3000 mg.
For children:
Single dose 250-500 mg, daily dose 750-2000 mg.
Course of treatment is 1-4 months, sometimes 6 months. A break of 3-6 months is required between courses of treatment.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3191967
Hopantenic acid inhibits the absorption of [14C]-GABA (0.2 uM) by the rat brain cortex slices (3 mm) incubated in calcium-free medium. The effect of Hopantenic acid manifests at its low concentrations (10(-6) M).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:10:06 GMT 2023
by
admin
on
Fri Dec 15 16:10:06 GMT 2023
|
Record UNII |
H473MVB16U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3280
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
HOPANTENIC ACID
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
28281
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
SUB08055MIG
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
DB14044
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110783
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
2649
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
100000083987
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
C83808
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
18679-90-8
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
H473MVB16U
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
DTXSID6048331
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
C016030
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | |||
|
m6053
Created by
admin on Fri Dec 15 16:10:06 GMT 2023 , Edited by admin on Fri Dec 15 16:10:06 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |